Making personalized medicine a reality requires alignment across health care stakeholders to allow patients access to advanced testing and treatment options. By collaborating across pharma companies, the Precision Cancer Consortium (PCC) has shown that by working together we can enable comprehensive genomic testing and bring forward the potential of molecularly guided therapy options. It is exciting to unite around a common goal of improving global patient access to comprehensive genomic testing and partner for impact on a global scale.